Prentice Wealth Management’s Viking Therapeutics VKTX Stock Holding History

Prentice Wealth Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-300	Closed	-$1K	–	177
2022 Q2	$1K	Buy	+300	New	+$742	﹤0.01%	136
2021 Q4	–	Sell	-300	Closed	-$2K	–	299
2021 Q3	$2K	Sell	300 -150	-33%	-$927	﹤0.01%	302
2021 Q2	$3K	Hold	450	–	–	﹤0.01%	288
2021 Q1	$3K	Buy	+450	New	+$3.17K	﹤0.01%	290

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Prentice Wealth Management's VKTX Position: Q3 2022 in Review

Prentice Wealth Management sold out of Viking Therapeutics (VKTX) in Q3 2022, closing a stake of 300 shares — an estimated $1K sold.

Prentice Wealth Management first reported a position in VKTX in Q1 2021 and held it in 4 quarters. The position peaked at $3K in Q2 2021. 107 funds tracked by Wall St. Rank hold VKTX as of Q3 2022.

Prentice Wealth Management reported no remaining Viking Therapeutics position as of Q3 2022 after selling out during the quarter.
Prentice Wealth Management sold 300 Viking Therapeutics shares in Q3 2022, an estimated $1K.
Prentice Wealth Management first reported a position in Viking Therapeutics in Q1 2021 and held it in 4 quarters.
Prentice Wealth Management's Viking Therapeutics position peaked at $3K in Q2 2021.
107 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2022.

Based on Prentice Wealth Management's 13F filing for Q3 2022, filed 19 Oct 2022.